



## Change of Company Secretary

1 April 2025

**LTR Pharma Limited (ASX:LTP) ("LTR Pharma" or "the Company")** advises that in accordance with ASX Listing Rule 3.16.1, that Mr David Hwang and Ms Elizabeth Spooner of Confidant Partners have been appointed as Joint Company Secretaries, effective immediately.

For the purposes of ASX Listing Rule 12.6, Mr David Hwang and Ms Elizabeth Spooner will be the persons responsible for communications with ASX in relation to Listing Rule matters. Ms Shelby Coleman will step down as Company Secretary, effective immediately. The Company thanks Ms Coleman for her support of the Board during her time with the Company.

- ENDS -

This announcement has been approved by the Board of Directors.

### About LTR Pharma

**LTR Pharma** is dedicated to improving men's health—physically and mentally—through the commercialisation of innovative treatments for erectile dysfunction. The Company's lead product, **SPONTAN®**, delivers a PDE5 inhibitor via a fast-acting intranasal spray, enabling onset of action in 10 minutes or less. This unique delivery method offers men greater control, spontaneity, and confidence, distinguishing SPONTAN® from conventional oral therapies.

LTR Pharma is focused on building a global footprint, leveraging regulatory milestones, strategic partnerships, and medical community engagement to address unmet patient needs.

### For further information please contact:

Media enquiries  
Haley Chartres  
[haley@hck.digital](mailto:haley@hck.digital)

Investor enquiries  
Peter McLennan  
[investors@ltrpharma.com](mailto:investors@ltrpharma.com)